Decisions facing the cystic fibrosis clinician at first isolation of Pseudomonas aeruginosa

Paediatric Respiratory Reviews

Volumn 3, Issue 1, 2002, Pages 82-88

  Bush, Andrew ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Antibiotics; Cystic fibrosis; Infection; Pseudomonas aeruginosa; Treatment

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; COLISTIN; PLACEBO; TIMENTIN; TOBRAMYCIN;

ADOLESCENT; ADULT; ANTIBIOTIC SENSITIVITY; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIUM ISOLATION; BRONCHITIS; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS INFECTION; CYSTIC FIBROSIS; DIAGNOSTIC ACCURACY; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG BLOOD LEVEL; DRUG CHOICE; GRAM NEGATIVE INFECTION; HUMAN; INFECTION CONTROL; LUNG FUNCTION; MEDICAL DECISION MAKING; PHENOTYPE; PHYSICIAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; SURVIVAL;

EID: 0036249430     PISSN: 15260550     EISSN: None     Source Type: Journal    
DOI: 10.1053/prrv.2002.0193     Document Type: Article

References (38)

1. Antibiotic therapy against P. aeruginosa in cystic fibrosis: A European Consensus
2. Microbiology of cystic fibrosis lung infections: Themes and issues
3. Microbial pathogenesis in cystic fibrosis: Mucoid Pseudomonas and Burkholderia cepacia
4. +-dependent mitogen-activated protein kinase signaling pathways in airway epithelial cells
5. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection
6. High mutation frequencies among Escherichia coli and Salmonella pathogens
7. Pseudomonas aeruginosa and cystic fibrosis: Unusual bacterial adaptation and pathogenesis
8. Host inflammatory responses to first isolation of P. aeruginosa from sputum in cystic fibrosis
9. Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonisation with Pseudomonas aeruginosa
10. Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype
11. Clinical outcome after acquisition of Burkholderia cepacia in patients with cystic fibrosis
12. Effects of Pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis
13. The Cystic Fibrosis Foundation Patient registry report 1996
14. Seasonal onset of initial colonisation and chronic infection with Pseudomonas aeruginosa in patients with cystic fibrosis in Denmark
15. Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis
16. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis
17. Effect of continuous antistaphylococcal therapy on the rate of P. aeruginosa acquisition in patients with cystic fibrosis
18. Longitudinal assessment of P. aeruginosa in young children with cystic fibrosis
19. Use of cough swabs in a cystic fibrosis clinic
20. Early pulmonary inflammation in infants with cystic fibrosis
21. P. aeruginosa infection in people with cystic fibrosis: Suggestions for prevention and infection control
22. Prevention of cross infection during outpatient spirometry
23. P. aeruginosa cross-infection among patients with cystic fibrosis during a winter camp
24. Genome finger printing of P. aeruginosa indicates colonization of cystic fibrosis siblings with closely related strains
25. Superinfection with a transmissible strain of P. aeruginosa in adults with cystic fibrosis chronically infected by P. aeruginosa
26. P. aeruginosa in cystic fibrosis: Cross-infection and the need for segregation
27. Spread of a multiresistant strain of P. aeruginosa in an adult cystic fibrosis clinic
28. Changing epidemiology of P. aeruginosa infection in Danish cystic fibrosis patients (1974-1995)
29. Microbiology of cystic fibrosis
30. Of isolates and isolation: P. aeruginosa in adults with cystic fibrosis
31. Prevention of chronic P. aeruginosa colonisation in cystic fibrosis by early treatment
32. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of P. aeruginosa colonization in cystic fibrosis
33. Antibiotic treatment of initial colonization with P. aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis
34. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis
35. Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis
36. Detection of Pseudomonas aeruginosa in sputum from cystic fibrosis patients by polymerase chain reaction
37. PCR identification of Pseudomonas aeruginosa and direct detection in clinical samples from cystic fibrosis patients